Biblio

Author Title [ Type

] Year

Filters: Author is Choquet, Sylvain [Clear All Filters]

Journal Article

Mahadeo KMichael, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicent. Lancet Oncol. 2024.

Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522.

Lesueur P, Damaj G, Hoang-Xuan K, Roland V, Schmitt A, Chinot O, Fabbro M, Agape P, Chabrot CMoluçon, Chebrek S, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: a LOC-network study. Blood Adv. 2022.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019:JCO1800306.

Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023.

Cailleteau A, Maingon P, Choquet S, Bourdais R, Antoni D, Lioure B, Hulin C, Batard S, Llagostera C, Guimas V, et al. Phase 1 study of the combination of escalated total marrow irradiation using helical Tomotherapy and fixed high-dose melphalan (140 mg/m²) followed by autologous stem cell transplantation at first relapse in multiple myeloma. Int J Radiat Oncol Biol Phys. 2022.

Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, Durot E, Willaume A, Gauthier M, Moles-Moreau M-P, et al. Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study. Blood Adv. 2021.

Younan N, Soussain C, Choquet S, Cassoux N, Touitou V, Schmitt A, Chinot O, Obéric L, Damaj G, Houot R, et al. Isolated intraocular relapses of primary cerebral lymphomas: AN LOC NETWORK STUDY. Hematol Oncol. 2022.

Chaganti S, Barlev A, Caillard S, Choquet S, Cwynarski K, Friedetzky A, González-Barca E, Sadetsky N, Schneeberger S, Thirumalai D, et al. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study. Adv Ther. 2023.

Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. Nat Med. 2023.

Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2024.